Concepedia

Mark DeBenedette

MD

Statistics

Publications

31

Citations

2.9K

H-Index

24

Active since

1991

Affiliations

Argos Therapeutics (United States)(Current)

University of Toronto

Cedars-Sinai Medical Center

Princess Margaret Cancer Centre

The University of Texas MD Anderson Cancer Center

Mark DeBenedette is an author at Argos Therapeutics (United States) specializing in immunology, life sciences, and immunotherapy.

Publications per year

1991–2020

31

Publications

31

4-1BB Ligand Induces Cell Division, Sustains Survival, and Enhances Effector Function of CD4 and CD8 T Cells with Similar Efficacy

Jennifer L. Cannons, Peggy Lau, Birinder Ghumman et al. · The Journal of Immunology · 2001 · 353 citations · Full text

Life Sciences, Cell Biology, Immunology +17

Costimulation of CD28- T lymphocytes by 4-1BB ligand

Mark DeBenedette, Arda Shahinian, Tak W. Mak et al. · The Journal of Immunology · 1997 · 321 citations · Full text

Life Sciences, Cell Biology, Immunology +17

CD28-independent, TRAF2-dependent Costimulation of Resting T Cells by 4-1BB Ligand

Katina Saoulli, Soo Young Lee, Jennifer L. Cannons et al. · The Journal of Experimental Medicine · 1998 · 318 citations · Full text

Life Sciences, Immunology, Immunoregulation +16

Analysis of 4-1BB Ligand (4-1BBL)-Deficient Mice and of Mice Lacking Both 4-1BBL and CD28 Reveals a Role for 4-1BBL in Skin Allograft Rejection and in the Cytotoxic T Cell Response to Influenza Virus

Mark DeBenedette, Tao Wen, Martin F. Bachmann et al. · The Journal of Immunology · 1999 · 279 citations · Full text

Life Sciences, Immunology, Pathology +17

Survival with AGS-003, an autologous dendritic cell–based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results

Asim Amin, Arkadiusz Z. Dudek, Theodore F. Logan et al. · Journal for ImmunoTherapy of Cancer · 2015 · 214 citations · Full text

Medicine, Immunology, Oncology +16

1–5 of 31